Pharma Publications at CPhI Worldwide 2018

Oct 9, 2018

In the heart of the action of ICSE Pharma Insights Briefings The international pharmaceutical networking exhibition, CPhI Worldwide 2018, is being held at – IFEMA, Feria De Madrid from 9th – 11th of October 2018. Over 3500 exhibitors and 36,000 trade visitors are using the strongest platform in the industry to meet outsource suppliers, build partnerships, to showcase or acquire products and services. The professionals belonging to this sector are exhibiting an advanced range of chemicals, products, services and equipment’s which will benefit the professionals working in this sector and help work efficiently. The traders find this platform to be ...

Read More

Spinraza® ▼ (nusinersen) Interim Data from Phase 2 Trial, NURTURE, Presented at Annual Congress of the World Muscle Society Demonstrate Benefits in Treating Presymptomatic Infants with Spinal Muscular Atrophy

Oct 9, 2018

At point of follow-up NURTURE all study participants were alive and did not require permanent ventilation, in contrast to natural history of spinal muscular atrophy (SMA)1 Study participants achieved motor milestones with 100 percent sitting independently and 88 percent able to walk with assistance1 Additional data feature biomarkers as an indicator for clinical development work in SMA Biogen Inc. (Nasdaq: BIIB) has announced new interim results from NURTURE, an ongoing open-label, single-arm efficacy and safety phase 2 study of Spinraza (nusinersen) in 25 presymptomatic infants with 5q SMA.1 The data were presented in a late-breaking session at the 23rd Annual ...

Read More

CRUK forges £30m ‘post-Brexit’ R&D alliance

Oct 2, 2018

Cancer Research UK has joined forces with two peer organisations in Italy and Spain to fund half a dozen R&D projects – and to show that Brexit need not be a hindrance to UK-EU cooperation. The link-up with Italy’s AIRC (Associazione Italiana per la Ricerca sul Cancro) and Spain’s FC AECC (Asociación Española Contra el Cáncer) will direct around £30m (around $40m) in funding towards translational research projects in cancer and particularly immuno-oncology. The awards will cover six projects, all operating under the banner of the Accelerator Award programme and will run over five years. Two are being led by ...

Read More

AstraZeneca chief on Brexit: “It’s going to be really painful”

Oct 2, 2018

AstraZeneca’s stockpiling of medicines ahead of Brexit is a temporary safeguard at best, and shortages could follow if no customs deal is agreed with the EU, according to CEO Pascal Soriot. In a pair of articles in the Times and Sunday Times, AZ’s CEO says the company has increased its medicine stocks by around 20%, and “wasted” some £40m ($53m) building laboratories in Sweden to duplicate product testing so that products can stay on the market. However, a ‘no deal’ outcome on customs could cause “more serious problems” given the complexity of the supply chain for medicines across Europe, with components shuttling back and forth ...

Read More

Janssen secures NHS England funding for HIV therapy Symtuza

Oct 2, 2018

Janssen Pharmaceutical has announced funding from NHS England (NHSE) for Symtuza to treat human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents aged 12 and above with at least 40kg of body weight. Symtuza is a once-daily darunavir-based single-tablet regimen (STR). It is a fixed-dose combination of four active substances – darunavir, cobicistat, emtricitabine and tenofovir alafenamide (D/C/F/TAF). The funding will enable clinicians across England to routinely prescribe D/C/F/TAF to eligible patients. Janssen-Cilag Health Economics, Market Access and Reimbursement (HEMAR) and Advocacy director Jennifer Lee said: “We are delighted that NHSE has provided vital funding for this treatment ...

Read More